BrainsWay Ltd. (NASDAQ:BWAY – Get Free Report) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 49,200 shares, an increase of 30.5% from the August 15th total of 37,700 shares. Based on an average trading volume of 69,800 shares, the days-to-cover ratio is currently 0.7 days.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on BWAY shares. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of BrainsWay in a research note on Monday. Northland Securities upped their price target on shares of BrainsWay from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th.
View Our Latest Analysis on BrainsWay
BrainsWay Price Performance
BrainsWay (NASDAQ:BWAY – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter. BrainsWay had a net margin of 1.67% and a return on equity of 1.45%. The company had revenue of $10.01 million during the quarter, compared to analysts’ expectations of $9.40 million. During the same quarter last year, the company posted ($0.05) EPS. On average, research analysts anticipate that BrainsWay will post 0.06 earnings per share for the current fiscal year.
Hedge Funds Weigh In On BrainsWay
Institutional investors and hedge funds have recently made changes to their positions in the company. Perritt Capital Management Inc bought a new stake in BrainsWay in the 2nd quarter valued at $121,000. Acadian Asset Management LLC boosted its position in shares of BrainsWay by 48.1% in the second quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock valued at $1,567,000 after acquiring an additional 84,371 shares during the period. Rhumbline Advisers grew its stake in shares of BrainsWay by 10.3% in the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after acquiring an additional 1,695 shares in the last quarter. Virtu Financial LLC bought a new position in BrainsWay during the first quarter worth about $60,000. Finally, Essex Investment Management Co. LLC increased its position in BrainsWay by 37.5% during the first quarter. Essex Investment Management Co. LLC now owns 324,843 shares of the company’s stock worth $1,718,000 after acquiring an additional 88,593 shares during the period. Institutional investors and hedge funds own 30.11% of the company’s stock.
BrainsWay Company Profile
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Read More
- Five stocks we like better than BrainsWay
- Why is the Ex-Dividend Date Significant to Investors?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- The 3 Best Fintech Stocks to Buy Now
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to Find Undervalued Stocks
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.